Cause and metabolic consequences of fatty liver. Hyperglycemia and hyperinsulinemia induce hepatic de novo lipogenesis via carbohydrate response element–binding protein (ChREBP) and sterol regulatory element–binding protein (SREBP)-1c, respectively, thereby increasing the hepatic pool of fatty acyl-CoAs. This pool is also increased by augmented delivery of free fatty acids (FFAs) either through the diet or lipolysis in adipose tissue. Fatty acyl-CoAs are assembled to TAGs that remain in the liver or are secreted in the form of VLDLs. The latter pathway is regulated by several factors, among them the two enzymes SCD1 and DGAT2 as well as the microsomal transfer protein (MTP) and the availability of apoliprotein B (ApoB). ELOVL6 and PNPLA3/adiponutrin are also involved in the process of hepatic TAG storage, while specific mechanisms of action are not fully understood. Finally, a low activity of the ATGL also results in storage of fatty acyl-CoAs in the form of TAGs, thereby contributing to the detoxification of hepatic lipids. This process can also be accelerated by hepatic oxidation of fatty acyl-CoAs involving the transcription factors PPAR-α and -δ. In addition, the AMP-activated kinase (AMPK) is involved. The adipokine adiponectin stimulates FA oxidation via AMPK activation and PPAR-α induction. AMPK is also involved in the suppression of lipogenesis. When these mechanisms of detoxification are overwhelmed or not active, lipotoxicity prevails resulting in hepatic inflammation and insulin resistance. Via dysregulation of secreted hepatokines (e.g., fetuin-A, SHBG, selenoprotein P), increased glucose production and dyslipidemia, fatty liver then also induces systemic subclinical inflammation, whole-body insulin resistance, hyperglycemia, and ultimately the manifestation of type 2 diabetes and cardiovascular disease.